Kisunla
Q2 2026 revenue $167M.
The numbers
Revenue$167MQ2 2026 · source ↗
What it is
Donanemab, an anti-amyloid antibody for early Alzheimer's disease, marketed in the US.
Why it matters to the stock. Kisunla is Lilly's neuroscience bet on Alzheimer's, and its growth is a test of the market for disease-modifying therapies.
News
No stories tagged to this project yet.